Skip to content

Expression of Endometrium During Window of Implantation

To Investigate the Expression of Endometrium During Window of Implantation Between Natural Cycles and Artificial Cycles

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05478616
Enrollment
3
Registered
2022-07-28
Start date
2022-07-01
Completion date
2023-12-31
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unrecognized Condition

Keywords

window of implantation, endometrium receptivity, frozen embryo transfer cycles, natural cycles, artificial cycles, hormone replacement therapy cycles

Brief summary

The aim of this study was to investigate the expression of endometrium during window of implantation between natural cycles and artificial cycles.

Detailed description

Due to progress of embryo vitrification in recent years, frozen embryo transfer (FET) of in vitro fertilization (IVF) has already been a world trend. The most used two protocols of FET are natural cycles (NCs) and artificial cycles (ACs). Recent studies showed that IVF outcomes of NCs were superior to ACs. We hypothesized that the result may be because of better endometrial receptivity of NCs compared to ACs. In NCs, no hormonal agents were administrated. Thus, endometrial receptivity was not disturbed by hormone and became better. However, there were few studies to explore the issue. Therefore, the aim of this study was to investigate the expression of endometrium during window of implantation (WOI) between NCs and ACs. The study will be performed from July 1st, 2022 to December 31th, 2023 in our reproductive center. We plan to enroll 60 infertile women who have underwent IVF cycles and would like to receive endometrial receptivity assay. We divide the participants into two groups, NCs and ACs. In NCs, no hormonal agents will be used. We identify ovulation day via serial hormone data and sample endometrium during WOI (LH surge + 7 days). In ACs, first, estrogen will be given for 10\ 14 days and then transvaginal sonography will be conducted. When endometrial thickness reaches 8 mm at least, progesterone will be prescribed. Endometrium is sampled during WOI (P4 + 5 days). We will record basic characteristics, infertility history, hormone data, ovarian reserve and endometrial thickness of infertile women in both groups. Endometrial samples will be assessed miRNA, implantation factors, uterine NK cells and T cells in both groups.

Interventions

None listed

Sponsors

Kaohsiung Veterans General Hospital.
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 44 Years
Healthy volunteers
No

Inclusion criteria

* Age: 30-44 years * BMI: 18\ 30 kg/m2 * Implantation failure at least two times

Exclusion criteria

* Primary ovarian insufficiency * Congenital uterine anomaly * Severe intrauterine adhesion * Malignancy * Donor cycle

Design outcomes

Primary

MeasureTime frameDescription
Expression of endometriumthrough study completion, an average of 1.5 yearmiRNA

Secondary

MeasureTime frameDescription
Implantation factors of endometriumthrough study completion, an average of 1.5 yearHOXA10
Immune cells of endometriumthrough study completion, an average of 1.5 yearUterine NK cells

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026